The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples